Hermes M, Malbica J O
J Pharm Sci. 1984 May;73(5):667-70. doi: 10.1002/jps.2600730519.
A high-performance liquid chromatographic (HPLC) method is reported that provides for either separate or simultaneous plasma determination of tracazolate and its major metabolite, the free carboxylic acid. Tracazolate is extracted from plasma with hexane and is quantitated by reverse-phase HPLC using an internal standard. The metabolite is extracted in an additional step, methylated, and either quantitated using the same HPLC conditions in a separate determination or combined with the hexane extract for the simultaneous HPLC determination of drug and metabolite. The plasma concentrations of metabolite were as much as 60 times greater than free drug in some animal species, therefore requiring the use of separate determinations for the two compounds. The analyses have limits of reproducible quantitation of 20 ng/mL for tracazolate and 50 ng/mL for the metabolite in plasma. The simultaneous analysis for tracazolate and the metabolite was used to evaluate plasma levels of both compounds versus time and dose. Data generated in conjunction with a toxicology study are reported to demonstrate the applicability of the procedure.
本文报道了一种高效液相色谱(HPLC)方法,该方法可单独或同时测定血浆中的曲卡唑及其主要代谢产物游离羧酸。曲卡唑用己烷从血浆中萃取,并用内标通过反相HPLC进行定量。代谢产物在额外的步骤中萃取、甲基化,然后在单独的测定中使用相同的HPLC条件进行定量,或者与己烷萃取物合并用于同时通过HPLC测定药物和代谢产物。在某些动物物种中,代谢产物的血浆浓度比游离药物高多达60倍,因此需要对这两种化合物进行单独测定。这些分析对血浆中曲卡唑的可重现定量限为20 ng/mL,对代谢产物为50 ng/mL。曲卡唑和代谢产物的同时分析用于评估两种化合物的血浆水平随时间和剂量的变化。报告了结合毒理学研究产生的数据,以证明该方法的适用性。